Objective: We compare different dosimetric parameters in cervical cancer patients receiving concurrent chemotherapy and three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT) and explore the incidence of hematological toxicity (HT) in these patients.
Methods: Twenty patients receiving 3DCRT or IMRT and 4 weekly doses of cisplatin (25 mg/m/w) were studied. The volumes of bone marrow receiving 10, 20, 30, 40 and 50 Gy or greater (V10, V20, V30, V40, and V50, respectively) were calculated. The HT was graded according to the guidelines of the Radiation Therapy Oncology Group system. The associations between dosimetric parameters and HT and chemotherapy delivery were analyzed.
Results: The bone marrows V30, V40, and V50 were lower in the IMRT group than in the 3DCRT group (62.93% vs 76.91%, 31.36% vs 39.60%, and 9.79% vs 15.44%, respectively). No statistical difference was observed for both V10 and V20. Acute hematologic toxicity occurred in both groups but was more frequent in the 3DCRT group. The percentage of patients with grade 2 and worse leukopenia and neutropenia was 90% and 80% in the 3DCRT group, whereas it was 80% and 40% in the IMRT group. The median nadir of white blood cells and the absolute neutrophil count were significantly lower in the 3DCRT group than in the IMRT group (1.96 × 10(9) vs 2.72 × 10(9) and 1.09 × 10(9) vs 1.86 × 10(9), respectively).
Conclusion: The IMRT reduced the volume of bone marrow irradiated at the higher doses and the incidence and severity of acute hematologic toxicity in cervical cancer patients undergoing concurrent chemoradiotherapy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215915 | PMC |
http://dx.doi.org/10.1097/IGC.0000000000000292 | DOI Listing |
Adv Radiat Oncol
January 2025
Department of Medical Imaging, Faculty of Allied Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Purpose: Current management for clinically localized prostate cancer in low- and middle-income countries (LMICs) includes surgery, external beam radiation therapy (EBRT), and brachytherapy either alone or in combination, with plus or minus hormone therapy. The toxicity profiles and oncological outcomes of these treatment modalities vary. This systematic review and meta-analysis aimed to determine the prevalence of treatment-related outcomes and toxicities for men diagnosed with localized prostate cancer in LMICs.
View Article and Find Full Text PDFRadiother Oncol
December 2024
IRCCS San Raffaele Scientific Institute, Medical Physics Dept., Milan, Italy. Electronic address:
Purpose: The aim is to train and validate a multivariable Normal Tissue Complication Probability (NTCP) model predicting acute skin reactions in patients with breast cancer receiving adjuvant Radiotherapy (RT).
Methods And Materials: We retrospectively reviewed 1570 single-institute patients with breast cancer treated with whole breast irradiation (40 Gy/15fr). The patients were divided into training (n = 878, treated with 3d-CRT, from 2009 to 2017) and validation cohorts (n = 692, treated from 2017 to 2021, including advanced RT techniques).
Front Oncol
December 2024
School of Nuclear Science and Engineering, East China University of Technology, Nanchang, Jiangxi, China.
Background: Volumetric-modulated arc therapy (VMAT) may have the highest overall performance for stereotactic body radiotherapy (SBRT) treatment of inoperable early-stage NSCLC. However, in centers lacking the VMAT technique, the dynamic conformal arc therapy (DCAT) technique is potentially the best option for small and rounded NSCLC-SBRT. Therefore, we will comprehensively analyze the advantages of the DCAT versus the other techniques except VMAT in terms of dosimetry, plan complexity, delivery time, γ-passing rates and the interplay effect.
View Article and Find Full Text PDFCancers (Basel)
November 2024
Icon Cancer Centre, 1-3 Macarthur Ave, Revesby, NSW 2022, Australia.
Adjuvant radiation therapy (ART) for macroscopic regional nodal cutaneous melanoma has evolved. A significant step was the discovery of targeted therapies, particularly towards V600E-mutated melanoma, and immunotherapy under its different kinds. Prior to this, the defining trial was the Australia and New Zealand Melanoma Trials Group (ANZMTG) 01.
View Article and Find Full Text PDFAm J Transl Res
November 2024
Department of Radiotherapy, Hebei Province Hospital of Chinese Medicine, Hebei University of Chinese Medicine Shijiazhuang 050011, Hebei, China.
Background: With clinical trials on the use of different modern precise radiotherapy techniques in the setting of postoperative radiotherapy (PORT) in N2 non-small cell lung cancer (NSCLC) accumulating, an updated meta-analysis was performed.
Methods: A literature search identified studies that investigated PORT versus non-PORT in N2 NSCLC patients. Overall survival (OS) and locoregional recurrence (LR) were employed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!